window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

NEO-811

  • Biotech,Clinical Trials,Drug discovery,Funding,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    April 18, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
  • Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed
    Categories: Clinical Trials, Immunology, Oncology, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top